Pancreatic Cancer Research

ResearcherUtrecht UniversityActive in the last 2 years

Marc G. Besselink

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2650-9350; OpenAlex author ID A5015416945, A5158309978, A5158562153. Sources: ClinicalTrials.gov.

Their work

Papers
293 (first author 11, last author 56)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
3
Collaborators
621
Papers, trials and grants by year

2014: 3 papers · 2015: 5 papers · 2016: 17 papers · 2017: 9 papers · 2018: 18 papers · 2019: 14 papers · 2020: 25 papers · 2021: 25 papers, 1 trial · 2022: 30 papers · 2023: 34 papers · 2024: 40 papers · 2025: 34 papers, 1 trial · 2026: 39 papers, 1 trial

Papers 50 of 293

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant T… Co-author DOI 10.1002/ijc.70519↗
  3. Restaging the primary tumor in localized pancreatic ductal adenocarcinoma after systemic therapy: a scoping review of the role of CT, FDG-PET, and CA19-9. Co-author DOI 10.1007/s00330-026-12954-1↗
  4. Refining the Classroom: The Self-Supervised Professor Model for Improved Segmentation of Locally Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s10278-025-01555-x↗
  5. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  6. Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A population-based study. Co-author DOI 10.1016/j.ejca.2026.116943↗
  7. The impact of lower household income and distance to hospital on treatment and survival in patients with localized pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116956↗
  8. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  9. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  10. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  11. Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. Co-author DOI 10.1016/j.hpb.2025.12.035↗
  12. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Last author DOI 10.1016/j.hpb.2026.04.453↗
  13. Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study. Co-author DOI 10.1016/j.hpb.2026.08.011↗
  14. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer - Authors' reply. Co-author DOI 10.1016/s1470-2045(25)00729-6↗
  15. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  16. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  17. Gastrointestinal symptoms and health-related quality of life before and after pancreatectomy for pancreatic cancer (GO-PANC): longitudinal nationwide study. Co-author DOI 10.1093/bjs/znag122↗
  18. Continuity of care experienced by patients diagnosed with pancreatic cancer: nationwide multicentre study. Co-author DOI 10.1093/bjsopen/zrag033↗
  19. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  20. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  21. Splenic hilum nodal involvement in resected left-sided pancreatic cancer: meta-analysis. Co-author DOI 10.1093/bjsopen/zrag153↗
  22. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. Co-author DOI 10.1093/jnci/djag024↗
  23. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consorti… Co-author DOI 10.1093/jnci/djag033↗
  24. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  25. Pain prevalence and intensity in advanced pancreatic cancer: a nationwide cohort study. Co-author DOI 10.1097/j.pain.0000000000004059↗
  26. Informing Decision-making for Transected Margin Reresection in Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer: An International Multicenter … Co-author DOI 10.1097/sla.0000000000006532↗
  27. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  28. Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. Co-author DOI 10.1097/sla.0000000000006660↗
  29. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Last author DOI 10.1097/sla.0000000000007025↗
  30. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  31. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18479-z↗
  32. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  33. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  34. ASO Author Reflections: Arterial Reconstruction in Pancreatic Cancer: Shifting from Anatomical Feasibility Towards Biological Selection. Co-author DOI 10.1245/s10434-026-19469-5↗
  35. Impact of R0/R1 Margin Status on Overall Survival in Node-Positive Resected Pancreatic Ductal Adenocarcinoma: Meta-Analysis. Last author DOI 10.1245/s10434-026-19850-4↗
  36. ASO Author Reflections: R0 Resection Should Not Be Dismissed in Node-Positive Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-026-20047-y↗
  37. Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancreatic Surgery Consorti… First author DOI 10.1245/s10434-026-20620-5↗
  38. ASO Visual Abstract: Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancre… First author DOI 10.1245/s10434-026-20742-w↗
  39. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  40. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  41. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  42. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  43. Survival scenarios of patients with localized and metastatic pancreatic adenocarcinoma: A population-based study. Co-author DOI 10.1002/ijc.35267↗
  44. Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis. Last author DOI 10.1016/j.ctrv.2025.102969↗
  45. Longitudinal health-related quality of life in patients with pancreatic cancer stratified by treatment: a nationwide cohort study. Co-author DOI 10.1016/j.eclinm.2024.103068↗
  46. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … Co-author DOI 10.1016/j.ejca.2025.115385↗
  47. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  48. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  49. Tumor gene expression is associated with venous thromboembolism in patients with ductal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.thromres.2024.109240↗
  50. Pancreatic cancer. Last author DOI 10.1016/s0140-6736(25)00261-2↗

Trials 3

  1. Spleen Preservation Versus Splenectomy in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID) Principal investigator NCT07799298↗
  2. Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3) Principal investigator NCT06939023↗
  3. PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer Principal investigator NCT05524090↗

Closest collaborators

The 25 strongest of 621 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bas Groot Koerkamp · 115 shared papers, 2017–2026 · strength 16.64
  2. Johanna W. Wilmink · 106 shared papers, 2015–2026 · strength 14.56
  3. Izaak Quintus Molenaar · 105 shared papers, 2014–2026 · strength 14.16
  4. Hjalmar C. van Santvoort · 90 shared papers, 2014–2026 · strength 12.41
  5. Ignace H. J. T. de Hingh · 88 shared papers, 2014–2026 · strength 11.34
  6. Casper H.J. van Eijck · 80 shared papers, 2014–2026 · strength 10.20
  7. Lois A. Daamen · 56 shared papers, 2017–2026 · strength 9.41
  8. Hanneke W.M. van Laarhoven · 69 shared papers, 2015–2026 · strength 8.80
  9. Bert A. Bonsing · 64 shared papers, 2014–2026 · strength 8.35
  10. Martijn W.J. Stommel · 53 shared papers, 2019–2026 · strength 7.97
  11. Judith de Vos‐Geelen · 49 shared papers, 2016–2026 · strength 7.33
  12. Vincent Erwin de Meijer · 48 shared papers, 2020–2026 · strength 7.29
  13. Geert Kazemier M · 45 shared papers, 2016–2026 · strength 6.54
  14. Marjolein Y.V. Homs · 40 shared papers, 2019–2026 · strength 6.26
  15. Lydia G. van der Geest · 40 shared papers, 2016–2026 · strength 5.51
  16. Sebastiaan Festen · 40 shared papers, 2016–2026 · strength 5.50
  17. Ammar A. Javed · 28 shared papers, 2019–2026 · strength 5.32
  18. Geertjan van Tienhoven · 41 shared papers, 2015–2026 · strength 5.16
  19. Thomas F. Stoop · 28 shared papers, 2021–2026 · strength 4.91
  20. Ingmar Florin Rompen · 22 shared papers, 2024–2026 · strength 4.20
  21. Christopher Lee Wolfgang · 25 shared papers, 2016–2026 · strength 4.18
  22. Gijs A. Patijn · 30 shared papers, 2016–2026 · strength 3.87
  23. Joseph R. Habib · 19 shared papers, 2024–2026 · strength 3.68
  24. Paul C. M. Andel · 20 shared papers, 2024–2026 · strength 3.68
  25. Mohammad Abu Hilal · 20 shared papers, 1 shared trial, 2016–2026 · strength 3.62

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.